title: [Blasch-kolinear psoriasis revealed by infliximab therapy].
abstract: BACKGROUND
  Blaschko-linear psoriasis is a rare disease about which only a few publications have appeared in the literature. This form of psoriasis poses problems of differential diagnosis with regard to other forms of inflammatory Blaschko-linear dermatoses. Herein, we report an original case, the linear nature of which was revealed by treatment with infliximab.
  
  
  METHODS
  A 29-year-old man presented chronic psoriasis present for 17 years and resistant to various forms of systemic therapy. Treatment with infliximab 5mg/kg given on D1, D15 and two-monthly, thereafter resulted in practically complete resolution of all skin lesions after the fourth infusion. The only remaining lesions were psoriatic erythematous-squamous, non-pustular lesions with a Blaschko-linear pattern, limited to one side, on the left arm and left leg. These lesions persisted after 10 courses of infliximab, although no other lesions reappeared.
  
  
  CONCLUSIONS
  This case was original in terms of the revelation of Blaschko-linear lesions during treatment with infliximab, despite the complete disappearance of diffuse psoriatic plaques, thus suggesting the existence in this patient of two cell populations, each having a different response to biotherapy.
authors.affiliation: Service de dermatologie, hôpital Pasteur, 39, avenue de la Liberté, 68024 Colmar cedex, France. sadokmehdi@yahoo.fr
authors.forename: M
authors.initials: M
authors.lastname: Sfia
authors.forename: B
authors.initials: B
authors.lastname: Roth-Mall
authors.forename: M-C
authors.initials: MC
authors.lastname: Tortel
authors.forename: J-C
authors.initials: JC
authors.lastname: Guillaume
authors.forename: B
authors.initials: B
authors.lastname: Cribier
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D002047:Buprenorphine / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D002047:Buprenorphine; D000069285:Infliximab; D008691:Methadone